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Abstract
Objectives—Clinical staging is widespread in medicine—it informs prognosis, clinical course
and treatment, and assists individualized care. Staging places an individual on a probabilistic
continuum of increasing potential disease severity, ranging from clinically at-risk or latency stage
through first threshold episode of illness or recurrence and finally to late or end-stage disease. The
aim of this paper was to examine and update the evidence regarding staging in bipolar disorder,
and how this might inform targeted and individualized intervention approaches.
Methods—We provide a narrative review of the relevant information.
Results—In bipolar disorder, the validity of staging is informed by a range of findings that
accompany illness progression, including neuroimaging data suggesting incremental volume loss,
cognitive changes, and a declining likelihood of response to pharmacological and psychosocial
treatments. Staging informs the adoption of a number of approaches, including the active
promotion of both indicated prevention for at-risk individuals and early intervention strategies for
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newly diagnosed individuals, and the tailored implementation of treatments according to the stage
of illness.
Conclusions—The nature of bipolar disorder implies the presence of an active process of
neuroprogression that is considered at least partly mediated by inflammation, oxidative stress,
apoptosis and changes in neurogenesis. It further supports the concept of neuroprotection, in that a
diversity of agents have putative effects against these molecular targets. Clinically, staging
suggests that the at-risk state or first episode is a period that requires particularly active and broad-
based treatment, consistent with the hope that the temporal trajectory of the illness can be altered.
Prompt treatment may be potentially neuroprotective and attenuate the neurostructural and
neurocognitve changes that emerge with chronicity. Staging highlights the need for interventions
at a service delivery level and implementing treatments at the earliest stage of illness possible.
Keywords
bipolar disorder; clinical staging; depression; early intervention; mania; neuroprogression;
treatment
Introduction
In a range of medical specialities, including cardiology and oncology, clinical staging forms
the basis of assessment, prognosis, and choice of therapies. In contrast, psychiatry has only
recently begun to use staging as a construct to understand the onset, progression and
outcome of psychiatric disorders. However, of late, there has been a substantial body of
emerging data on this topic. The purpose of this paper is to examine and update the evidence
regarding staging in bipolar disorder, and how this might inform targeted and individualized
intervention approaches.
Staging is widely used in medicine, particularly for disorders such as cancer, heart and liver
disease. According to this model, illnesses progress through identifiable phases that have
specific features and consequently require tailored interventions. For example, in breast
cancer, the Tumour, Node, Metastasis (TNM) staging model ties the clinical phenotype and
extent of disease progression in three related domains; this is documented to refine
diagnosis, tighten prognosis and assist in treatment selection. Staging in cancer highlights
the imperative of early diagnosis and intervention, as survival may depend on the timely
application of effective treatment. In medicine, clinical staging describes where an
individual’s presentation exists on a temporal spectrum of disorder progression. The models
generally begin at stage 0 (defined as an at risk, or latency stage) through to stage IV,
operationalized as late stage disease (1). There is acceptance that this concept reflects an
aggregate picture, and that stepwise progression through serial phases may not be applicable
to all patients with a particular disorder (Table 1).
Staging implies a number of potentially testable hypotheses, which have been largely
validated in medicine, particular oncology and cardiology. The first is that the natural
history of the disorder moves through a predictable temporal progression. Secondly,
provision of timely and stage appropriate treatment can modify the individual’s pattern of
disease progression. Thirdly, prognosis is more favourable with earlier diagnosis and
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treatment, and treatments used earlier have a more favourable risk-benefit ratio than those
used later. Lastly, the effects of early intervention can alter the distribution of the stages in
the population over time (1, 2).
The clinical stages define the extent of disease progression at any particular point in time as
well as where a person currently lies along a continuum of the described course of an illness.
A staging template refines clinical choice, assisting clinicians to choose treatments relevant
to a particular stage of illness. For example, in the treatment of schizophrenia, clozapine is
typically used in the later stages of treatment, while public health interventions or indicated
prevention is adapted to the asymptomatic or at risk stages. Such interventions address
potentially plastic risk factors for the genesis or progression of disorders (3). The model
assumes that interventions will be simultaneously more effective and less harmful if
delivered earlier in the treatment course.
An implicit aim of staging is to prevent progression to advanced stages of a disorder and
facilitate regression to earlier and more benign stages. The hope, supported by evidence for
example that lithium increases grey matter volume, is that appropriate therapy can both
prevent neuroprogression, and have neuroprotective effects (4). It is thus necessary to
understand the diverse and interacting genetic, environmental, social, biological, and
psychological protective and risk factors that mediate or moderate the process of disease
progression (2, 5, 6). These factors need to be understood in aggregate for a particular
disorder, as well as for an individual person, in order to develop personalised approaches to
care. Risk factors may vary in their impact on different stages; some may impact all stages,
whereas others may be stage-specific. For example, sexual abuse may increase risk in a non-
specific manner for the onset phase of diverse disorders, and operate across several or all
stage transitions; with adherence and engagement potentially influencing risk of transition to
later stages (7).
Clinical evidence supporting staging
Staging in psychiatry has a long history. A century ago, Kraepelin first suggested that
psychiatric disorders had a staged progression, and his view of their progressive nature was
reflected in his nomenclature of dementia praecox. In 1993, Fava and Kellner (8) described
staging as a “neglected dimension in psychiatric classification”. Staging was subsequently
operationalized around schizophrenia, and staging models have been adapted and proposed
for bipolar disorder (2, 5, 9), unipolar depression (10, 11), eating disorders (12), and
agoraphobia (13). However, in contrast to staging in medical illnesses where anatomic
extent and impact of the disease determine stage, staging models in psychiatry have been
based on a course-based definition of phase of illness, using duration and relapse criteria in
defining stages (9).
In psychiatry, staging models described categories in a model compatible with medical
staging models. These categories ranged from Stage 0 (describing an at-risk phase for a
disorder without any clear symptoms), through Stages 1a and 1b (reflecting mild, non-
specific and identifiable prodromal symptoms respectively), Stage 2 (defined as the first
episode), Stages 3a, 3b, and 3c (defined as subthreshold, threshold, and persistent relapses
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respectively), to Stage 4 (reflecting persisting unremitting symptoms that are potentially
non-responsive to treatment) [for a review, see (1)]. There is a twist in this model for bipolar
disorder, as according to the DSM system, one has to have a manic or hypomanic episode to
be bipolar. Since depression usually is the index episode, there is a consequent mismatch
between the model and the DSM classification of the disorder. It is therefore prudent that we
allow index depression, under a unipolar rubric, to be added to the broader phenotype.
A number of clinical lines of evidence support the validity of staging. The first data showing
that psychiatric disorders having a progressive and potentially deteriorating course were
those of Kraepelin, who observed with each episode, that periods of wellness between
relapses in bipolar disorder often become shorter and that each recurrence catalyses
vulnerability to further illness. This finding that has been robustly replicated prompted the
suggestion of a progressive underlying neuropathology, the nature of which has only
recently begun to be elucidated.
The second key line of evidence are studies that show stage related differences in the
efficacy of therapies at differing phases in the temporal course of bipolar disorder.
Gelenberg et al. (14), Swann et al. (15), and Franchini et al. (16) have shown that the
efficacy of lithium is consistently reduced with successive episodes. A similar pattern has
been shown with atypical antipsychotics, where a study examined pooled data of 4,346
participants in twelve studies of an atypical antipsychotic in the treatment of bipolar
disorder. Those at the earliest stages of illness consistently had a more favourable response
to treatment on measures of mania, depression, overall global impression, and relapse (17).
In the Systematic Treatment Enhancement Program for Bipolar Disorder database, number
of episodes was robustly related to ratings of mania, depression, functioning and quality of
life. In addition, the suggestion of possible efficacy of antidepressants in early stage illness
was not seen in later stages (18).
A similar pattern is seen in studies of psychological treatments for bipolar disorder. While
Lam et al. (19) suggested that cognitive behavioral therapy (CBT) is effective in preventing
or delaying relapse independent of the number of previous episodes, other studies for
example, the largest trial of CBT for bipolar disorder to date, Scott et al. (20), challenge this.
Specifically this study revealed that psychological intervention was more effective in those
in the early stages, between episodes 1–6, and that CBT led to higher relapse rates compared
to treatment as usual amongst people who had more than 30 episodes. Similarly, Reinares et
al. (21) and Colom (22) showed that those who had the smallest number of previous
episodes had the greatest benefit from psychoeducation.
Neuroprogression
At the foundation of the staging model is the concept of neuroprogression, which has been
demonstrated as a characteristic of numerous psychiatric disorder (21, 46). This has its
origins in the work of Post and colleagues (11), who first coined the concept of
neurosensitisation, and adapted the concept of kindling to apply to mood disorders in 1986.
Early attempts to understand the underlying neurobiological mechanisms focussed on
cortisone and the monoamines, but this has broadened considerably in recent years.
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Neurogenesis, apoptosis, oxidative, mitochondrial, and inflammatory mechanisms are
gaining traction as key components of the phenomena underlying the progression of
psychiatric disorders including bipolar disorder, and the consequences including treatment
non-responsiveness (23). These shared novel pathways may also go some way to explaining
the effectiveness of medications as different as lithium, valproate and antipsychotic
medications, which have all been found to influence neurotrophins, neurogenesis, apoptosis,
inflammatory pathways and oxidative biology (24). These pathways will be discussed in
more depth in succeeding sections of this paper.
Perhaps the most important neurobiological biomarker of staging is neuroimaging evidence
of structural changes. In contrast to research in schizophrenia, which has shown that
hippocampal volume loss and ventricular dilatation may occur prior to the first episode of
schizophrenia, the data suggests, albeit with inconsistencies, that in bipolar disorder, gross
brain structure is relatively preserved during its early phases (25). Paralleling this,
progressive neuropsychological changes unfold during the course of the disorder (26),
supporting the presence of neuroprogressive changes over time. Strakowski et al. (27) has
shown that individuals with a first-episode of mania had ventricular size comparable to
controls, whereas individuals with recurrent illness showed ventricular enlargement. With
chronicity, progressive loss of grey matter thickness over time is also described (27, 28).
There is however conflicting data, in that ‘ultra-high risk’ individuals prior to a threshold
first-episode of mania had reductions in amygdala and insular volume (A. Bechdolf,
personal communication). There may thus be both early differences that are
neurodevelopmentally mediated (29), in addition to regionally specific neuroprogressive
changes.
A consequence of the structural changes in bipolar disorder is the decline in cognitive
functioning, which is a well-documented feature, and a major driver of secondary disability
(30). Cognitive change may be related to the number of prior illness episodes (31, 32).
López-Jaramillo et al. (26) compared cognitive functioning in first, second and third episode
groups, and showed that people who have had a first- or second-episode displayed minimal
cognitive differences from controls, whereas individuals with three or more episodes
diverged on most measures of cognition compared to both early-episode patients with
bipolar disorder and controls.
That multiple episodes can result in long term alterations in neuronal systems was first
described by Goddard and adapted by Post in his kindling model (33). With the progression
of illness, it was thought that there is a failure of endogenous compensatory mechanisms
(10). McEwan’s concept of allostatic load hypothesis similarly captures a progressive “wear
and tear” process, in which life stressors and genetic load, interact with aggravating factors
such as substance abuse (34), setting up a vicious cycle capable of aggravating the core
neuropathology of the disorder, which can further disrupt the brain circuits that are
responsible for mood regulation and cognition, which further increases vulnerability to
illness. The operative elements of this biochemical process of neuroprogresssion include the
dopaminergic system, oxidative stress, inflammatory cytokines, endoplasmic reticulum
stress, mitochondrial dysfunction and neurotrophins including brain-derived neurotrophic
factor (BDNF) (10, 35, 36).
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Elevated levels of cytokines are one of the best established biomarkers of both depression
and mania (36). Kauer-Sant’Anna et al. (37) first described stage related changes in
cytokines, noting specifically that the pro-inflammatory cytokines IL6 and TNFα were
elevated in both early and late stage disorder, while the anti-inflammatory cytokine IL10
was increased in the early stage, but not the late stage of the disorder. Conversely, TNFα,
was higher in the later stages. Similar stage dependant changes in oxidative biology have
been found at later stages of the illness such that in individuals with bipolar disorder
compared to those in the early stages and controls, the activity of glutathione reductase, and
glutathione transferase, which are key enzymes in the glutathione pathway, are increased
(38). Further, neurotrophins such as BDNF, which play a key role in neuronal survival and
proliferation, also show stage dependant changes, and while maintaining normal levels in
the early stages of the disorder, measurably decrease in its later stages (37, 39). These stage
related changes in the neurotrophins, oxidative and inflammatory system may be due to
either failure of adaptive homeostatic mechanisms as part of neuroprogression, or
progression of the primary underlying disease process.
Methodological caveats
A number of methodological caveats are necessary in interpreting the data. The concept of
staging is heuristic, and is an exploratory framework. Almost all studies are cross sectional
in nature, and prospective studies that follow cohorts over time are necessary to definitively
confirm the results of the cross sectional findings. Importantly, individuals’ illness
trajectories can vary widely, with some people having a good or poor outcome at the onset
of disorder; some individuals only having a single episode of illness, and others manifesting
a malignant pattern from the outset. A challenge confronted by the staging model is the
necessity to account for the inter- as well as intra-individual variability in functional
outcomes in individuals with bipolar disorder. Many individuals with substantial illness
burden continue to function at a high level as well as the converse. There are important
moderator effects of temperament, social networks and support and occupational complexity
and environmental resources. There is a risk of tautology, inasmuch as those people belong
to either pattern might cluster in different stages of the model. It is therefore unclear to what
extent this influences classification, and to what extent true illness progression accounts for
in the model, as both are likely to be simultaneously operative. While we do have intriguing
biomarker data suggesting stage related changes, this is not yet of a nature that allows an
analogue of the TNM model to be developed.
Substantive clinical heterogeneity exists; biomarker and neuroimaging structural changes
may vary for different individuals with similar clinical histories, and individuals who have
experienced the same number of illness episodes may have different clinical presentations
and different levels of functioning. The role of comorbid illness in the staging model is not
defined, but is a feature of most mental illness.
Clinical implications of staging
If the thesis holds that there is plastic process of disease progression, and that this is
amenable to intervention, then the best opportunity for effective treatment may be that of
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early intervention. For this to occur, the first necessary step is accurate diagnosis.
Intervention may be theoretically possible as early as in the ultra-high risk stage, and criteria
to identify such individuals have been validated (40, 41). Bipolar disorder is however often
initially misdiagnosed, largely because the index presentation is that of depression, and the
prodrome is even more non-specific, with anxiety, substance use, mood lability, sleep
change and diffuse behavioral change typical; in contrast, mania, which usually occurs some
years later, is required for diagnosis (42, 43). Mania, which can be ego-syntonic, or can
present with psychosis, is consequently not always easy to diagnose (44). As a result, 69%
of people with bipolar disorder are misdiagnosed at least once (9), and there is a delay over
12 years between initial onset of symptoms and commencement of treatment (10).
Early intervention has the potential to prevent or minimise the secondary morbidity that
arises because of progressive episodes (45). A clinical course marked by multiple episodes
is associated with consequent employment and financial difficulties, a deleterious impact on
relationships, and the development of self-esteem issues, guilt and loss, which serves as a
secondary stressor, perpetuating illness (20). As a disorder with an onset in adolescence or
early adulthood, it occurs during a normative and critical phase in an individual’s emotional,
educational and psychosocial development. One of the goals of age- and stage-dependant
intervention is to minimise disruption to a person’s normal developmental trajectory. This
can be achieved through an integrated approach combining effective psychopharmacology
and evidence-based psychosocial interventions, including CBT, social rhythm based
approaches, psychoeducation, medication adherence, relapse prevention, social and
vocational recovery, and assisting with family and caregiver adaptation to the disorder
(46-48).
Conclusions
Concordant with established use in medicine, and following initiatives in psychosis research,
staging models are now of value on the basis of the clinical trajectory of bipolar disorder,
differences in response to therapies and biomarkers including neuroimaging, cognition and
biochemistry. Staging suggests that interventions may have differential utility at different
phases of the disorder, and that treatments should be tailored, amongst other factors, to the
phase of the disorder. This paradigm is inherently optimistic. It suggests deployment of
appropriate biological and psychosocial interventions in the early phases of bipolar disorder
as they could prevent the secondary consequences of the illness, including neuroprogression
and secondary morbidity, and might have neuroprotective potential, as well as the promise
of preventing or reducing stage progression. This is predicated on timely and accurate
diagnosis, and highlights the importance of service initiatives to allow implementation of
these goals.
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Table 1
A potential clinical staging model for bipolar disordera
Clinical stage Definition Potential interventions
0 Increased risk of severe mood disorder (e.g.,
family history, abuse, substance use)
No specific current symptoms
Mental health literacy
Self-help





1b Prodromal features: ultra-high risk 1a plus therapy for episode: phase
specific or mood stabilizer
2 First episode threshold mood disorder 1b and case management, vocational
rehabilitation, specific psychotherapy
3a Recurrence of sub-threshold mood symptoms 2 and emphasis on maintenance
medication and psychosocial
strategies for full remission
3b First threshold relapse 2a and relapse prevention strategies
3c Multiple relapses 3b and combination mood stabilizers
4 Persistent unremitting illness 3c and clozapine and other tertiary
therapies, social participation despite
disability
aAdapted with permission from McGorry et al. 2006 (1).
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